Alto Neuroscience, Inc.

NYSE:ANRO

Biotechnology

Healthcare
$25.91 +1.84%

+$0.40 today

Market cap
$1.04B
Beta
1.25
P/E (TTM)
-9.8
EPS (TTM)
-$2.26
52W Low $2.15High $28.44

Volume 0.99M

Average 0.34M

ANRO Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Alto Neuroscience, Inc.NYSE: ANRO

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $2.82M rose 43.5% year over year, ahead of the -5.4% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at +66.3% a year.

Context

  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +43.5% holds above the trailing-twelve-month pace of -5.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.82M— QoQ
Last fiscal yearDec 2025
$8.11M+6.3% YoY
LTMMar 2026
$7.02M-5.4% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+43.5%——
1 year+6.3%——
3-year CAGR+66.3%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
8.11M USD
Year-over-year change
+6.3%
4-year CAGR
+144.5%

Stock-Based Compensation vs competitors

How ANRO compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -5.4% is the 3rd highest of 9, against a peer median of -29.4%.
  • Over three fiscal years its annual growth of +66.3% compares with a peer median of +2.1%.
ANRO Competitors
Stock-Based Compensation for ANRO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SLNSilence Therapeutics plcLTM Mar 2026$14.34M USD—-14.0%1556.3%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$11.29M USD+31.2%+73.3%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$7.15M USD-15.9%+1.9%—
ANROAlto Neuroscience, Inc.LTM Mar 2026$7.02M USD-5.4%+66.3%—
DBVTDBV Technologies S.A.LTM Mar 2026$5.99M USD+37.2%+2.3%—
KRROKorro Bio, Inc.LTM Mar 2026$4.8M USD-10.4%+88.7%125.0%
AMRNAmarin Corporation plcLTM Mar 2026$3.95M USD-191.3%—1.8%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$2.88M USD-66.7%-9.8%—
ACIUAC Immune S.A.LTM Dec 2025CHF 2.68M CHF-42.8%—75.0%
CLLSCellectis S.A.LTM Mar 2026$1.28M USD-60.6%—1.9%
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$0 USD———
Peer median (excluding ANRO) —-29.4%+2.1%75.0%

Competitors are the stored peer set for ANRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(9.19M)(27.71M)(36.31M)(61.43M)(63.24M)
Depreciation & Amortization145K342K373K502K661K
Deferred Income Tax00000
Stock-Based Compensation227K1.76M2.89M7.63M8.11M
Change in Working Capital(572K)4.58M(698K)4.06M33K
Accounts Receivables(1.29M)1.16M325K00
Inventory00000
Accounts Payables458K1.01M(632K)516K221K
Other Working Capital255K2.42M(391K)3.54M(188K)
Other Non-Cash Items125K632K291K1.81M2.67M
Operating Cash Flow(9.26M)(20.39M)(33.45M)(47.42M)(51.77M)
Capital Expenditures(680K)(732K)(470K)(2.08M)(24K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(680K)(732K)(470K)(2.08M)(24K)
Debt Repayment09.83M01.25M9.48M
Common Stock Issued7K43K181K137.58M50.7M
Common Stock Repurchased0000(167K)
Dividends Paid00000
Other Financing Activities(205K)(341K)(2.05M)(3.14M)67K
Financing Cash Flow31.69M43.79M68.13M135.69M60.08M
Effect of Forex Changes(50K)(24K)(8K)(11K)(30K)
Net Change in Cash21.7M22.64M34.2M86.18M8.26M
Free Cash Flow(9.94M)(21.13M)(33.92M)(49.5M)(51.79M)

Alto Neuroscience, Inc.

NYSE:ANRO

Intrinsic Alpha fair value

Locked

Current Price

$25.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.